A recent Phase III FLAURA trial demonstrated the superiority of osimertinib over first-generation EGFR inhibitors gefitinib and erlotinib as a first-line treatment for EGFR-mutated NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.